Guideline on clinical investigation of new medicinal products for the treatment of acute coronary syndrome (CPMP/EWP/570/98)

Draft

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draft agreed by Cardiovascular Working Party</td>
<td>February 2016</td>
</tr>
<tr>
<td>Adopted by CHMP for release for consultation</td>
<td>1 April 2016</td>
</tr>
<tr>
<td>Start of public consultation</td>
<td>27 April 2016</td>
</tr>
<tr>
<td>End of consultation (deadline for comments)</td>
<td>31 October 2016</td>
</tr>
</tbody>
</table>

This guideline replaces 'Points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) without persistent ST segment elevation' (CPMP/EWP/570/98).

Comments should be provided using this template. The completed comments form should be sent to CVSWPSecretariat@ema.europa.eu.

Keywords

| Acute coronary syndrome, STE-ACS, NSTEMI, guideline, CHMP |
Table of contents

Executive summary ........................................................................................................... 4
1. Introduction (background) ....................................................................................... 4
2. Scope ......................................................................................................................... 5
3. Legal basis and relevant guidelines ........................................................................... 5
4. Choice of efficacy criteria (endpoints) ..................................................................... 6
  4.1. All-cause mortality and CV mortality ................................................................. 6
  4.2. New myocardial infarction ................................................................................... 6
  4.3. Revascularisation ................................................................................................. 6
  4.4. Unstable angina pectoris necessitating hospitalisation ........................................... 6
  4.5. Stent thrombosis .................................................................................................. 6
  4.6. Stroke .................................................................................................................. 7
  4.7. Left ventricular function and heart failure ............................................................ 7
  4.8. Composite endpoints .......................................................................................... 7
  4.9. Endpoints in fibrinolysis studies ........................................................................... 7
5. Methods to assess efficacy (how to measure the endpoints) ................................ 8
  5.1. Mortality .............................................................................................................. 8
  5.2. New myocardial infarction ................................................................................... 8
  5.3. Revascularisation ................................................................................................. 8
  5.4. Unstable angina pectoris necessitating hospitalisation ........................................... 8
  5.5. Stent thrombosis .................................................................................................. 8
  5.6. Ventricular function and heart failure ................................................................. 9
  5.7. Angiographic endpoints ....................................................................................... 9
6. Selection of patients ............................................................................................... 9
  6.1. Study population ................................................................................................. 9
  6.1.1. STE-ACS (ST elevation acute coronary syndrome) ......................................... 9
  6.1.2. NSTE-ACS (Non-ST elevation acute coronary syndrome) .......................... 9
  6.1.3. Unstable angina ............................................................................................. 9
  6.2. Inclusion criteria for the therapeutic studies ...................................................... 10
  6.3. Exclusion criteria for the therapeutic studies ...................................................... 10
  6.4. Risk Stratification .............................................................................................. 10
  6.5. Special populations ........................................................................................... 11
  6.5.1. Older patients .............................................................................................. 11
7. Strategy and design of clinical trials .................................................................... 11
  7.1. Clinical pharmacology ...................................................................................... 11
  7.2. Therapeutic exploratory studies ........................................................................ 12
  7.2.1. Objectives .................................................................................................... 12
  7.2.2. Design .......................................................................................................... 12
  7.3. Confirmatory Therapeutic Studies ..................................................................... 12
  7.3.1. Objectives .................................................................................................... 12
  7.3.2. Background therapy .................................................................................... 12
  7.3.3. Choice of comparator .................................................................................. 13
7.3.4. Duration of clinical studies ................................................................. 13
7.3.5. Analyses and subgroup analysis .......................................................... 13

8. Safety aspects ....................................................................................... 14
  8.1. Bleedings .......................................................................................... 14
  8.2. All-cause mortality ........................................................................... 15
  8.3. Thrombocytopenia .......................................................................... 15
  8.4. Rebound effect ................................................................................ 15
  8.5. Effects on laboratory variables ......................................................... 15
  8.6. Effects on concomitant diseases ...................................................... 15

References ............................................................................................... 16
Executive summary

Two CHMP Guidelines have been previously developed to address clinical investigations of new medicinal products for the treatment of acute coronary syndrome (ACS): (I) the CHMP points to consider (PtC) on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome without persistent ST-segment elevation (CPMP/EWP/570/98), published in 2000 [1], and (II) the CHMP PtC on the clinical development of fibrinolytic products in the treatment of patients with ST segment elevation myocardial infarction (CPMP/EWP/967/01), published in 2003 [2]. Since their finalisation, major developments have taken place in the definitions, diagnosis, interventions and management of ACS, as reflected in the relevant European Society of Cardiology (ESC) clinical practice guidelines (3, 4). Currently, an update of the above mentioned CHMP Guidelines is considered necessary to take these new developments into consideration based on literature review and experience gained with medicinal products intended for treatment during the acute phase and beyond. The present update includes the following changes: 1) guidance addressing both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), as well as unstable angina (UA), 2) update in their definitions, 3) risk stratification using different scoring systems, 4) investigated endpoints, and 5) clinical developments of new medicinal products beyond the acute stage, including agents other than antiplatelets and anticoagulants.

1. Introduction (background)

Cardiovascular diseases are currently the leading cause of death in industrialized countries and also expected to become so in emerging countries by 2020 [3, 4]. Among these, coronary artery disease (CAD) is the most prevalent manifestation and is associated with high mortality and morbidity. ACS has evolved as a useful operational term to refer to any constellation of clinical symptoms that are compatible with acute myocardial ischemia. It encompasses (STEMI), NSTEMI, and UA.

ACS represents a life-threatening manifestation of atherosclerosis. It is usually precipitated by acute thrombosis induced by a ruptured or eroded atherosclerotic coronary plaque, with or without concomitant vasoconstriction, causing a sudden and critical reduction in blood flow. In the complex process of plaque disruption, inflammation was revealed as a key pathophysiological element. Non-atherosclerotic aetiologies are rare e.g. such as arteritis and dissection.

ACS represents a life-threatening manifestation of atherosclerosis. It is usually precipitated by acute thrombosis induced by a ruptured or eroded atherosclerotic coronary plaque, with or without concomitant vasoconstriction, causing a sudden and critical reduction in blood flow. In the complex process of plaque disruption, inflammation was revealed as a key pathophysiological element. Non-atherosclerotic aetiologies are rare e.g. such as arteritis and dissection.

The leading symptom of ACS is typically chest pain. Patients with acute chest pain and persistent (>20 min) ST-segment elevation have ST-elevation ACS (STE-ACS) that generally reflect an acute total coronary occlusion. Patients with acute chest pain but without persistent ST-segment elevation have rather persistent or transient ST-segment depression or T-wave inversion, flat T waves, pseudonormalization of T waves, or no ECG changes. At presentation, based on the measurement of troponins, it is possible to further discriminate between the working diagnosis of non-ST-elevation ACS (NSTEMI) and unstable angina.

NSTEMI (7% vs. 3–5%, respectively), but at 6 months the mortality rates are very similar in both conditions (12% and 13%, respectively) [5,7,8]. Long term follow-up shows that death rates were higher among patients with NSTE-ACS than with STE-ACS, with a two-fold difference at 4 years [8]. This difference in mid- and long-term evolution may be due to different patient profiles, since NSTE-ACS patients tend to be older with more co-morbidities, especially diabetes and renal failure.
2. Scope

The aim of this guideline is to provide guidance when performing trials to develop medicinal products in the management of ACS. The primary goals of therapy for patients with ACS are to:

1. Treat acute, life-threatening complications of ACS, such as serious arrhythmias, pulmonary oedema, cardiogenic shock and mechanical complications of acute myocardial infarction (AMI). [9]
2. Reduce the amount of myocardial necrosis that occurs in patients with AMI, thus preserving left ventricular (LV) function, preventing heart failure (HF), and limiting other cardiovascular complications.
3. Prevent major adverse cardiac events like death, non-fatal myocardial infarction (MI), and need for urgent revascularization.

The focus in this Guideline concerns mainly the medical treatment of ACS (treatment goals 2 and 3). The choice of interventional procedures [percutaneous coronary intervention (PCI) or coronary artery bypass graft CABG)] falls outside the scope of this guideline.

3. Legal basis and relevant guidelines

This guideline has to be read in conjunction with the introduction and general principles and parts I and II of the Annex I to Directive 2001/83 as amended.

Pertinent elements outlined in current and future EU and ICH guidelines, should also be taken into account, especially those listed below:

- Dose-Response Information to Support Drug Registration (ICH E4; CPMP/ICH/378/95).
- Statistical Principles for Clinical Trials (ICH E9; CPMP/ICH/363/96).
- Choice of Control Group and Related Issues in Clinical Trials (ICH E10; CPMP/ICH/364/96).
- Points to consider on an Application with 1) Meta-analyses 2) One pivotal study (CPMP/EWP/2330/99).
- Points to consider on multiplicity issues in clinical trials (CPMP/EWP/908/99).
- Investigation of subgroups in confirmatory clinical trials (EMA/CHMP/539146/2013).
- The Extent of Population Exposure to Assess Clinical Safety for Drugs (ICH E1A; CPMP/ICH/375/95).
- Pharmacokinetic Studies in Man (3CC3A).
- Reporting the Results of Population Pharmacokinetic Analyses (CHMP/EWP/185990/06).
- Reflection paper on the extrapolation of results from clinical studies conducted outside the EU to the EU-population (EMEA/CHMP/EWP/692702/2008).
- Draft Guideline on clinical investigation of medicinal products for the treatment of chronic heart failure (EMA/392958/2015)
4. Choice of efficacy criteria (endpoints)

Definitions of clinical endpoints in confirmatory trials should be in line with the relevant clinical guidelines to facilitate interpretation of the results, to allow comparisons across clinical studies and to extrapolate to clinical practice. Endpoints should be centrally adjudicated by a blinded committee. The following endpoints are relevant to the investigation of efficacy in patients with ACS.

4.1. All-cause mortality and CV mortality

As one of the goals of treatment of ACS is reduction of mortality, this is an important endpoint to measure. There is an ongoing debate around the use of all-cause versus cardiovascular mortality in cardiovascular (CV) trials. All cause mortality is the most important endpoint in clinical trials for the estimation of the benefit-risk balance of a drug, in particular when investigating newer medicinal products with possible safety issues. On the other hand, CV mortality is more specifically linked to the mode of action of CV medicinal products/intervention and is especially relevant when the earliest part of the follow up is assessed. The choice is also dependent on the objective of the study i.e. in non-inferiority trials, CV mortality may be preferred while in superiority trials all cause mortality is usually used. In fibrinolysis studies, all cause mortality is preferred (see section 4.9).

As such, one of the two mortality endpoints should be included as a component of the primary endpoint, with the other investigated as a key secondary endpoint.

4.2. New myocardial infarction

New onset MI is a relevant endpoint in studies of ACS and should always be investigated. The definition of MI has evolved through the years; at the time of drafting of this Guideline, the third universal definition of MI is applicable [10]. Criteria of MI are the same as those used to define the index event (see below).

4.3. Revascularisation

Some clinical trials have included revascularization endpoints (PCI or CABG) as part of the primary composite with conflicting results [11, 12]. Such endpoints are considered more relevant to interventional studies, and in the scope of this Guideline, their inclusion as a primary endpoint should be clearly justified and their assessment pre-defined and systematically assessed.

4.4. Unstable angina pectoris necessitating hospitalisation

Unstable angina has been investigated in ACS clinical trials. Due to the varying definitions used, the associated subjectivity and the influence of local clinical practice, this endpoint is not encouraged to be included in the composite primary endpoint.

4.5. Stent thrombosis

Stent thrombosis (ST) is a rare event that can have fatal consequences. ST has been captured in some registration studies, but not consistently in the primary endpoint (PEP). The investigation of ST as part of the primary endpoint is not encouraged due to the uncertainty of the clinical relevance of all captured events, except for the “definite” subcategory. Another category identified by the timing is
intra-procedural stent thrombosis (IPST), which is a rare event indicating the development of occlusive or non-occlusive new thrombus in or adjacent to a recently implanted stent before the PCI procedure is completed. Some recent studies [13,14] show that these events may be of prognostic value. As such they should also be collected and presented as secondary endpoint but not included in the analysis of ST.

### 4.6. Stroke

Stroke should be defined by a generally accepted definition [15]. Clinical studies in ACS have used non-fatal stroke in the primary endpoint, including any types of strokes. However it is preferred to include only ischemic strokes in the primary endpoint, as this is the true measure of efficacy; haemorrhagic stroke should be included as a safety endpoint. An ischaemic stroke with haemorrhagic conversion should be considered as "primary ischaemic". The subgroup of "undefined strokes" should be as small as possible in order to be able to properly assess the effect of the study treatment. In case all types of strokes are included in the primary endpoint, a sensitivity analysis including only ischemic stroke should be submitted.

### 4.7. Left ventricular function and heart failure

Some medicinal products such as modulators of reperfusion injury or inflammation, or gene/cell therapy are developed to improve myocardial function and reduce the occurrence of HF. In these cases, measurement of myocardial function could be a relevant endpoint to investigate the mechanism of action. In phase III studies, these endpoints can be investigated as secondary endpoints to support the clinical endpoints. Occurrence of HF should be considered as a clinical endpoint in phase III studies aimed at showing benefit in long-term cardiovascular outcome. All-cause mortality and long term follow-up are mandatory in studies with novel interventions.

### 4.8. Composite endpoints

Due to the rather low incidence of cardiovascular events during the follow-up period after the acute phase of the ACS, composite endpoints consisting of relevant components are acceptable, both as primary and secondary endpoints. The composite of CV death, non-fatal MI and non-fatal stroke (Major Adverse Cardiovascular Events, [MACE]) has commonly been used in registration studies, with non-fatal strokes showing limited contribution to the results. As such, it is preferred to investigate the composite of death and non-fatal MI in confirmatory studies; non-fatal ischaemic stroke could be included in the composite if justified. Sometimes different definitions of MACE are being used with novel therapies [16], that should be justified when used in place of MACE. The inclusion of less objective and clinically derived outcomes in the same composite is generally not encouraged, as they may either drive the efficacy or dilute the results. In case these endpoints are included they have to be stringently defined, and adjudicated. Each component of the primary composite endpoint should be analysed as secondary endpoint.

The net clinical benefit that includes both benefit and safety issues of the studied drug may be used as a secondary endpoint to be evaluated if it contributes to the discussion on the benefit-risk balance of the studied drug.

### 4.9. Endpoints in fibrinolysis studies

In fibrinolysis studies, angiographic studies using the TIMI (Thrombolysis in Myocardial Infarction) perfusion grades as evaluation criteria are often used. However, complete recanalization cannot be considered as a surrogate for survival when assessing fibrinolytic drugs, as some medicinal products...
providing higher complete recanalization rates than alteplase, failed to demonstrate additional survival benefit. For this reason, all cause mortality is the most relevant endpoint or a combined endpoint as previously discussed (see 4.1). Secondary endpoints such as heart failure hospitalisations, left ventricular function, ventricular arrhythmias, the need for rescue recanalization (emergent and/or planned) should also be considered and justified.

5. Methods to assess efficacy (how to measure the endpoints)

5.1. Mortality

Definition of CV death should be clearly defined, in line with acceptable standards [17]. It is mandatory to report and centrally adjudicate all mortality data where survival is an endpoint of the study. Assessment of cardiovascular mortality will require censoring of other “types” of mortality, which may complicate its interpretation, in particular when non-CV deaths are in high proportion.

5.2. New myocardial infarction

The diagnostic of MI is based on the detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin (cTn)) with at least one value above the 99th percentile upper reference limit (URL). All MIs should be collected and also classified by their different sub types (i.e, spontaneous, secondary to an ischemic imbalance, related to PCI, related to ST or CABG) [10]. This is particularly important considering the different prognostic values of each type of MI. For the same reason and to support the clinical relevance of post procedural MIs, these events should be presented with higher cut-off values (≥ 5 and ≥10x upper level of normal ULN, in case of CK-MB or ≥70x ULN of cTn) [18]. These higher cut-off values can also help in diagnosing MIs in the setting of elevated baseline biomarkers, which is a problematic situation. In such cases, serial measurements of the biomarkers are necessary, in addition to new ECG changes or signs of worsening of cardiac function, e.g. HFor hypotension [18].

5.3. Revascularisation

The underlying cause of revascularization should be identified: restenosis, ST or disease progression. In the latter case target vessel revascularization (TVR) could be included. Early target lesion events after revascularization (before 30 days) are more likely to be caused by an angiographic complication and should preferably be included as safety endpoint (see ST).

5.4. Unstable angina pectoris necessitating hospitalisation

When investigated, robust definitions should be employed. In order to support the seriousness of the event it should also be shown that it has led to a revascularisation procedure. Since a medicinal product that prevents death and/or new MI might result in more patients suffering from UA, the analysis of this endpoint should take into account censoring issues as well.

5.5. Stent thrombosis

ST should be collected and classified as definite, probable and possible in line with acceptable definitions [19]. In addition, the timing of ST should be documented (acute, sub-acute, late and very late), as risk factors and clinical sequels differ with timing.
5.6. Ventricular function and heart failure

Investigation of cardiac function should follow state of the art methods. This can include among others measurement of ventricular function by isotopic method and/or by cardiac magnetic resonance imaging and/or echocardiography. Investigation of HF should follow the relevant CHMP guidelines.

5.7. Angiographic endpoints

Angiograms should undergo central blinded reading. In principle, the rate of TIMI 3 flow (complete revascularization) of the infarct related artery at 90 minutes is considered the most relevant angiographic endpoint, as it has been shown to correlate with an improved outcome in terms of mortality and left ventricular function. An earlier evaluation of the patency pattern (i.e. 30 and 60 minutes) may provide important information on the speed of recanalization. Whatever is the time-point selected as primary outcome, it must be properly justified and pre-specified in the clinical trial.

6. Selection of patients

6.1. Study population

The definition of the different ACS subtypes should be based on current guidelines/universal definition of MI including STEMI and NSTEMI as well as UA [3, 4, 10].

6.1.1. STE-ACS (ST elevation acute coronary syndrome)

In patients with acute chest pain and persistent (>20 min) ST-segment elevation on ECG the diagnostic of STE-ACS is made [3]. This condition generally reflects an acute total coronary occlusion. Most patients will ultimately develop an ST-elevation myocardial infarction (STEMI) with the criteria of acute myocardial infarction described before [see 5.2].

6.1.2. NSTE-ACS (Non-ST elevation acute coronary syndrome)

In patients with acute chest pain but no persistent ST-segment elevation the diagnostic of NSTE-ACS is made [4]. ECG changes may include transient ST-segment elevation, persistent or transient ST-segment depression, T-wave inversion, flat T waves or pseudo-normalization of T waves or the ECG may be normal. The clinical spectrum of non-ST-elevation ACS (NSTE-ACS) may range from patients free of symptoms at presentation to individuals with ongoing ischaemia, electrical or haemodynamic instability or cardiac arrest. The pathological correlate at the myocardial level is cardiomyocyte necrosis (NSTEMI) or, less frequently, myocardial ischaemia without cell loss (UA). Currently, cardiac troponins play a central role in establishing a diagnosis and stratifying risk, and make it possible to distinguish between NSTEMI and UA [4].

6.1.3. Unstable angina

Unstable angina (UA) is defined as myocardial ischemia at rest or minimal exertion in the absence of cardiomyocytes necrosis, i.e. without troponin elevation. Among NSTE-ACS population, the higher sensitivity of troponin has resulted in an increase in the detection of MI [4]; the diagnosis of UA is less frequently made.
6.2. **Inclusion criteria for the therapeutic studies**

Inclusion of both STEMI and NSTEMI and/or NSTE-ACS patients in the same clinical trial (or not) should be justified based on the mechanism of action of the investigated product and the proposed time of intervention. If both subgroups are investigated in the same trial, both subgroups should be well represented. For interventions aimed at post-acute and longer term phases (secondary prevention or plaque stabilisation) it may be justified to address both conditions in the same clinical trial. Time of inclusion of the patients in relation to the index event should be set and adequately discussed *a priori*.

Patients with unstable angina represent a different risk category and prognosis that necessitates different interventions than NSTEMI patients. However, during the acute presentation of NSTE-ACS it may be difficult to discriminate NSTEMI from UA so both groups have been included in some clinical studies. In general, the investigation of interventions in these patients is encouraged, but preferably in separate clinical trials.

If fibrinolysis is considered, inclusion criteria should be in line with the current treatment guidelines concerning the inclusion for fibrinolysis [3].

6.3. **Exclusion criteria for the therapeutic studies**

If the patients do not fulfil the above criteria for ACS they should be excluded from the ACS studies.

Other life-threatening conditions presenting with chest pain, such as dissecting aneurysm, myopericarditis or pulmonary embolism may also result in elevated troponins and should always be considered as differential diagnoses [4].

If drugs interfering with the haemostatic system are tested, patients with a significant risk of bleeding (e.g. recent stroke, recent bleeding, major trauma or surgical intervention) and/or a propensity to bleed (e.g. thrombocytopenia, clotting disturbances, intracranial vascular diseases, peptic ulcers, haemophilia) should be excluded from participation in the clinical studies.

Attention should be paid to the time elapsed between a previous application of antiplatelet or anticoagulant acting agent beforehand and the administration of study drug (e.g. the pharmacokinetic [PK] and even more importantly, the pharmacodynamic [PD] half-life of these previously administered drugs).

For reasons of generalisability of the study results to the future target population it is strongly advised not to define the exclusion criteria too narrow, i.e. polymorbid patients (e.g. renal and/or hepatic impairment, heart failure), should not automatically be excluded from the main therapeutic clinical trials.

When fibrinolysis is considered, exclusion criteria for fibrinolysis should be strictly respected [3].

6.4. **Risk Stratification**

In clinical trials, the ability of the therapy to demonstrate a treatment effect may depend on the underlying risk and expected event rates. Enrichment strategies are sometimes used in trials to obtain the required number of events with a reasonable time in specific subgroups who are likely to exhibit a higher event rate than the overall target population and potentially larger treatment effect. In that case, it has to be shown that the results of this enriched study population can be extrapolated to the general population.
In addition to traditional risk factors, phase III studies may recruit a broader patient population in whom risk scores are evaluated to identify signals of differential/consistent treatment (or safety) responses across levels of the risk score. International guidelines recommend the use of risk scores such as the Global Registry of Acute Coronary Events (GRACE) or TIMI in the clinical care of patients with ACS. These scores can be used to predict the risk of major cardiovascular events (MACE), and they are useful to guide treatment decisions. In addition, there are scores to characterise the bleeding risk e.g. CRUSADE in NSTEMI [4]. The use of biomarkers other than troponins for risk stratification necessitates further investigation [e.g. markers of ischemia and inflammation (ischemia-modified albumin, heart fatty acid binding protein)](20). From a regulatory perspective, risk scores should either be reported or adequate data should be provided in the study files to enable risk score calculations. Risk-based analyses can contribute to the interpretation of study results, especially in highly heterogeneous populations, although such analyses may not always be conclusive given the recognized limitations of subgroup analyses. Analysis among different risk setting using risk scores should be pre-defined and foreseen in the protocol. The assessment of subgroups formed by the categories of the risk score may reveal the need for further prospective studies or post-marketing surveillance priorities in specific subgroups.

6.5. Special populations

6.5.1. Older patients

Adequate representation of older patients (above 70 years) in the clinical trials should be ensured. The overall database of the dossier should be examined for the presence of age-related differences, e.g., in adverse event rates, in effectiveness, and in dose-response. If these relatively crude overview analyses show important differences, further evaluation may be needed. Special attention should be given to the frequently associated comorbidities in the ACS population in general and older patients in particular (diabetes mellitus, COPD, renal failure, anaemia), also in relation to the possible drug-drug interactions.

7. Strategy and design of clinical trials

7.1. Clinical pharmacology

The objectives of studies related to clinical pharmacology are the investigation of the PD and PK properties of the medicinal product in healthy volunteers, uncritically ill patients of both sexes and in patients with different degrees of renal and hepatic impairment as relevant. Furthermore, interactions of the new substance especially with mandatory/probable co-medications which are routinely used in the management of ACS (e.g. platelet inhibitors, anticoagulants as well as other CV medications) should be investigated. Comprehensive advice on interaction studies is provided in the CHMP Note for Guidance on the Investigation of Drug Interactions (CPMP/EWP/560/95).

PD studies should include evaluations of mechanism, onset and duration of action, as well as a preliminary investigation of tolerability. The PD activity of the new substance should be defined as much as possible, for example with regard to effects on haemostatic and haemodynamic variables.
7.2. Therapeutic exploratory studies

7.2.1. Objectives

The purpose of this development phase is to identify those patients with ACS who may benefit from the medicinal product and to establish suitable therapeutic dose ranges - usually as adjunctive therapy to existing standard treatment.

These early clinical trials often primarily aim at measuring drug activity. However, it is encouraged to investigate clinical endpoints as secondary or exploratory endpoints. As some medicinal products (e.g. parenteral agents) may be intended for limited duration of administration, investigation of transition from and to other oral agents should be conducted.

Furthermore, initial information on safety should be obtained and dose schedules should be defined for older patients and those with risk factors.

7.2.2. Design

Dose ranging studies should be performed using a randomised, controlled, double-blind design.

Different dosages should be tested for the projected duration of the treatment period.

The duration of these studies is - among other criteria - dependent upon the (primary) target variable(s) and the extent of clinical information they are aiming at. Mostly, it is useful to include a sufficiently long-term follow-up in order to estimate the incidence of significant clinical events and delayed adverse drug reactions (e.g. thrombocytopenia).

7.3. Confirmatory Therapeutic Studies

7.3.1. Objectives

The objectives of these studies are to provide robust evidence of efficacy establishing reduction of clinically relevant cardiovascular events (e.g. death/new MI) at a predefined time justified by the mechanism of action and duration of administration. These studies should also establish the safety of the new substance at the posology proposed for marketing (the dose schedule selected for pivotal studies should be justified on the basis of the results of the dose-finding studies in the target population). Longer follow-up are required when long term treatment are given after ACS, with the goal to decrease cardiovascular recurrences.

The majority of the main therapeutic studies will use composite endpoints as primary efficacy variables. Optimally, the different components of the composite will contribute to the positive results. Studies aiming at the proof of efficacy must have a confirmatory statistical approach. These studies must be controlled, randomised and every effort should be made to maintain double blindness. The statistical approach e.g. a demonstration of superiority, equivalence or non-inferiority, has to be pre-specified in the protocol.

In some cases (e.g. large scale, multicentre, multinational trial) a single confirmatory trial could be sufficient for the proof of efficacy of a new substance if the results are statistically persuading and clinically relevant as discussed in the relevant CHMP guideline (see section 3).

7.3.2. Background therapy

In general, background therapy should reflect the standard of care as recommended by current clinical guidelines [3,4]. However, actual availability of guideline-recommended treatments could depend on
external factors such as time delays in the uptake of new ACS therapies, differences in local clinical practice, local reimbursement policies, and availability of specific therapies. Alternatively, EU Registry data can be helpful to determine the standard of practice and can inform the design of pivotal studies. Background therapy is also relevant in the context of the used revascularisation strategy. The degree to which background therapy should be specifically standardized in terms of interventions, timing, drugs, and dosing will depend on the study drug’s mechanism of action or the specific question being addressed by the randomized controlled trial. This may eventually have to be reflected in the labelling.

7.3.3. Choice of comparator

Depending on the class of drug tested and its mechanism of action, placebo and/or active controlled trials may be adequate for the late development phases. Whenever plausible and adequate (i.e. different mechanism of action than that of standard therapy) the investigational drug or placebo should be given in addition to standard therapy. The choice of the active comparator can be challenging as it faces the same issues as standardisation of the background therapy i.e. possible disparity between guideline recommendations and regional standards of care. The appropriate comparator should be clinically relevant and correspond to current medical practice with an adequate evidence base.

7.3.4. Duration of clinical studies

For medicinal products intended for short-term administration (e.g. hours to 7 days), the primary endpoint should preferably be measured at 30 days following initiation of therapy in the confirmatory studies. Depending on the mechanism of action of the investigated drug - shorter time spans when measuring the primary endpoint may be acceptable if the follow-up data prove durability of efficacy. In any case, further measurements should be performed after longer (e.g. 180 days) but also after shorter duration (e.g. at time of termination of study drugs) as secondary measures of efficacy. In case of longer duration of administration, an appropriately chosen duration of follow-up should be pre-specified in the protocol in order to estimate longer-term efficacy and safety. The maintenance of an adequate benefit risk balance should be demonstrated. Long term results should preferably also be adjudicated by a blinded clinical event committee. Claims of chronic administration (following ACS) necessitate support from sufficiently long studies to demonstrate that a positive benefit risk balance is maintained throughout the administration period and according to the pre-defined hypothesis or to the number of events calculated (in case of events driven design).

7.3.5. Analyses and subgroup analysis

The database for the primary analysis, either investigator or - preferably - event adjudication committee adjudicated endpoints - has to be pre-specified in the protocol. A primary analysis based on the data produced by the event adjudication committee is especially important if side effects of the test drug or the comparator may eventually unblind some of the patients. Regarding the primary analysis, the total event rates at the pre-specified time points or time-to-event within this period can be chosen. However, in any case survival curves over this period - and also over the-follow-up period - should be provided for the combined endpoint and all its components in order to evaluate and whether or not differences occur. The components of a composite efficacy endpoint should be analysed individually in order to evaluate their contribution to the overall results. Optimally, the results of all components of the composite endpoint should point in the right direction. In a hierarchical view, the component “all cause mortality”
will be considered as being the most relevant (e.g. an over-mortality cannot be compensated by a
decreased rate in angina pectoris).

At least, randomisation should be stratified for region (if applicable) and the qualifying condition
(STEMI, NSTEMI and UA). Other risk factors (gender, age) may be considered for stratification of the
randomisation, in addition. Subgroup analyses for these factors should be presented. Subgroup
analyses for gender, age, risk score (section 6.4) as well as for revascularisations (e.g. CABG, PCI,
fibrinolysis) should be foreseen in the protocol in order to demonstrate consistency of the results.

In addition, subgroup analyses regarding patients with different cut-offs of elevated troponin I/T
concentration at enrolment, as well as those regarding differences in duration between symptom onset
and initiation of study drugs (e.g. < 6 hours, > 6 or 12 hours) are of increasing interest.

8. Safety aspects

During the course of the clinical trials all adverse events should be carefully documented. For large
scale outcome trials, a hierarchy of safety reporting can be considered, the most important being
bleeding and all-cause death. Careful consideration should be given to those patients who died -
especially while on therapy - or who failed to complete the study per protocol (in particular drop-outs
due to adverse events/drug reactions or lack of efficacy).

Safety in high-risk groups (e.g. patients with organ dysfunction, older age, extremes of body weight)
requires special consideration. Furthermore, any information available concerning clinical features and
therapeutic measures in accidental overdose should be provided.

Special efforts should be made to investigate potential adverse drug reactions that are characteristic
for the class of drug being tested, in particular those listed below.

8.1. Bleedings

Bleeding is the main complication of antithrombotic and antiplatelet therapy. Similar to the efficacy
evaluation, the adjudication of bleeding events by a central independent and blinded committee of
experts, using pre-specified limits and clear terms of reference is strongly encouraged.

In dose-finding studies, the use of a sensitive safety endpoint to assess bleeding risk, like the sum of
major and clinically relevant non-major bleeding, is recommended.

In pivotal trials, the recommended primary safety endpoint is major bleeding, but the sum of major
and clinically relevant non-major bleeding should be analysed as well (secondary endpoint).

The description of the severity (i.e.: life-threatening versus non-life-threatening major bleed),
localisation (i.e.: intracranial, gastrointestinal, etc.) and temporal pattern (i.e.: time-to-event analysis)
is encouraged.

Bleedings should be categorised according to an acknowledged classification. Different bleeding
definitions have been used in the setting of ACS; this heterogeneity impairs the interpretation of the
safety profile across trials. Consensus has not been reached on a unified classification. TIMI (i.e. TIMI
major and minor) and GUSTO (The Global Use of Strategies to Open Occluded Arteries) criteria for
example, have been previously used and have been shown to be independently correlated with
subsequent risk of death. The Bleeding Academic Research Consortium (BARC) undertook an initiative
to standardize reporting, but the proposed bleeding classification needs to be validated [21]. Dual
reporting of bleeding events using both the TIMI and BARC definitions could be considered for future
clinical trials and/or regulatory submissions to improve the comparative assessment of safety endpoints across medicinal products and trials.

In addition, the inclusion of ISTH major bleeding may be helpful to compare major bleeding rates of similar compounds across different indications (e.g., in comparison with stroke prevention in atrial fibrillation and/or treatment of VTE).

It is advisable to use the same classification for bleedings throughout the whole clinical development program. A subgroup analysis of bleedings regarding patients undergoing invasive procedures (e.g. PCI, CABG surgery) - or not - is necessary.

Transfusions of blood, red blood cells and/or coagulation factors are further indicators of bleeding severity and should thus be documented carefully (number, temporal association to application of study drug and/or procedure).

### 8.2. All-cause mortality

All cause mortality is usually part of the efficacy evaluation, but should also be included as part of the safety assessment to inform about mortality throughout the study period.

### 8.3. Thrombocytopenia

In particular heparins and platelet aggregation inhibitors are known to cause (acute and delayed) thrombocytopenia that can be severe and the cause of serious bleedings or other complications (e.g. heparin-induced thrombocytopenia in case of heparins). Consequently thrombocyte values have to be monitored closely during and after therapy. In cases with thrombocytopenia, information on degree, recovery time and outcome should be provided. Moreover, it has to be documented in detail (number, temporal association to study drug/procedure etc.) if transfusions of thrombocytes had become necessary.

### 8.4. Rebound effect

The studies should include the evaluation of events which are considered to be characteristic for a possible rebound effect (e.g. clear increase in angina pectoris and/or new MI and/or death and/or other thrombotic events) after termination of the study drug.

### 8.5. Effects on laboratory variables

The therapeutic clinical studies should include the investigation of effects on the white and red blood cell count and should especially focus on the question whether the observed changes can be explained by former bleeding. In addition, particular attention should be paid to increases in liver enzymes, creatinine concentration and possible antibody formation.

### 8.6. Effects on concomitant diseases

The studies should include the evaluation of effects of the new drug on the function of diseased organs (e.g. kidneys in case of renal impairment).
References


2. EMA – CPMP – Points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with ST segment elevation acute myocardial infarction (CPMP/EWP/967/01).


